Endomyocardial biopsy and ultrastructural changes in dilated cardiomyopathy: Taking a 'deeper' look into patients' prognosis

European Heart Journal

Volumn 36, Issue 12, 2015, Pages 708-710

  Savvatis, Konstantinos ^a   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GADOLINIUM; HEMOGLOBIN; MICRORNA;

ACUTE HEART FAILURE; APOPTOSIS; ATRIAL FIBRILLATION; CARDIAC IMAGING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CELL HYPERPLASIA; CELL ULTRASTRUCTURE; CONGESTIVE CARDIOMYOPATHY; EDITORIAL; ELECTRON MICROSCOPY; FAMILY HISTORY; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL READMISSION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MORBIDITY; MYOCARDITIS; MYOFILAMENT; NEW YORK HEART ASSOCIATION CLASS; PERIPARTUM CARDIOMYOPATHY; PRIORITY JOURNAL; PROGNOSIS; SUDDEN CARDIAC DEATH; FEMALE; MALE; PATHOLOGY; ULTRASTRUCTURE;

CARDIOMYOPATHY, DILATED; FEMALE; HEART FAILURE; HUMANS; MALE; MYOCYTES, CARDIAC;

EID: 84940025059     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu461     Document Type: Editorial

References (20)

1. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-1084.
2. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010; 31:2677-2687.
3. Goldberger JJ, Buxton AE, Cain M, Costantini O, Exner DV, Knight BP, Lloyd-Jones D, Kadish AH, Lee B, Moss A, Myerburg R, Olgin J, Passman R, Rosenbaum D, Stevenson W, Zareba W, Zipes DP. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation 2011;123:2423-2430.
4. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, Boehmer JP, Carlson MD, Frantz RP, McNulty SE, Rogers JG, Anderson J, Johnson GW, Walsh MN, Poole JE, Mark DB, Lee KL, Bardy GH. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 2009;120:2170-2176.
5. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-691.
6. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
8. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009;301:383-392.
9. Karlstrom P, Alehagen U, Boman K, Dahlstrom U. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 2011;13:1096-1103.
10. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y, O'Hanlon R, Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013;309:896-908.
11. Mattos BP, Zettler CG, Pinotti AF, Raudales JC, Zago AJ. Left ventricular function and endomyocardial biopsy in early and advanced dilated cardiomyopathy. Int J Cardiol 1998;63:141-149.
12. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger A, Bohm M. Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118:639-648.
13. Escher F, Kuhl U, Lassner D, Stroux A, Westermann D, Skurk C, Tschope C, Poller W, Schultheiss HP. Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome. Eur J Heart Fail 2014;16:1066-1072.
14. Kuhl U, Lassner D, von Schlippenbach J, Poller W, Schultheiss HP. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol 2012;60:1295-1296.
15. Lassner D, Kuhl U, Siegismund CS, Rohde M, Elezkurtaj S, Escher F, Tschope C, Gross UM, Poller W, Schultheiss HP. Improved diagnosis of idiopathic giant cell myocarditis and cardiac sarcoidosis by myocardial gene expression profiling. Eur Heart J 2014;35:2186-2195.
16. Kuhl U, Rohde M, Lassner D, Gross UM, Escher F, Schultheiss HP. miRNA as activity markers in Parvo B19 associated heart disease. Herz 2012;37:637-643.
17. Escher F, Lassner D, Kühl U, Gross U, Westermann D, Poller W, Skurk C, Weitmann K, Hoffmann W, Tschöpe C. Analysis of endomyocardial biopsies in suspected myocarditis-diagnostic value of left versus right ventricular biopsy. Int J Cardiol 2014;177:76-78.
18. Saito T, Asai K, Sato S, Takano H, Mizuno K, Shimizu W. Ultrastructural features of cardiomyocytes in dilated cardiomyopathy with initially decompensated heart failure as a predictor of prognosis. Eur Heart J 2015;36:724-732.
19. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet 2010;375:752-762.
20. Kostin S. Pathways of myocyte death: implications for development of clinical laboratory biomarkers. Adv Clin Chem 2005;40:37-98.